Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
December 11, 2017 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma ...
Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
December 11, 2017 02:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma ...
Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate
November 13, 2017 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate ~ Data shows a 73% one-year...
Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate
November 13, 2017 02:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate ~ Data shows a 73% one-year survival...
Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
October 31, 2017 08:01 ET
|
Immunocore Limited
PRESS RELEASE Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (Oxford, UK and...
Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
October 31, 2017 03:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (Oxford, UK and Conshohocken,...
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
October 04, 2017 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer (Oxford, UK and Conshohocken, US, 4 October 2017) Immunocore Limited, the world's leading TCR company...
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
October 04, 2017 02:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer (Oxford, UK and Conshohocken, US, 4 October 2017) Immunocore Limited, the world's leading TCR company developing...
Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases
September 18, 2017 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases $40 million investment to accelerate development of...
Immunocore announces third oncology target selected in discovery collaboration with GlaxoSmithKline
July 03, 2017 02:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore announces third oncology target selected in discovery collaboration with GlaxoSmithKline (Oxford, UK and Conshocken, US, 3 July 2017) Immunocore Limited, the...